港股異動 | 多重利好疊加 康方生物-B續升7%
格隆匯12月8日丨昨日大漲逾18%的康方生物-B(9926.HK)再度拉昇漲超7%,報39.75港元,總市值334億港元。日前公司宣佈與Summit Therapeutics就AK112(PD-1/VEGF雙抗)達成合作協議,總交易金額達50億美元。交銀國際認為,授權金額創紀錄進一步證明了公司走向國際化的實力。報吿又提到,該公司週一(5日)宣佈決議將在科創板上市,預計其融資金額將超過20億元,為公司的研發提供更充足的資金保障。另外,卡度尼利單抗將參與2022年醫保談判,預計治療費用降至每年10萬元,將是近期股價催化劑。該行上調康方生物明年收入預測,維持買入評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.